Abciximab reduces mortality in diabetics following percutaneous coronary intervention

Journal of the American College of Cardiology

Volumn 35, Issue 4, 2000, Pages 922-928

  Bhatt, Deepak L ^a   Marso, Steven P ^a   Lincoff, A Michael ^a   Wolski, Katherine E ^a   Ellis, Stephen G ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; PLACEBO;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DRUG MECHANISM; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; MORTALITY; OBESITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034654627     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00650-6     Document Type: Article

References (58)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234.
2. Cohen Y., Raz I., Merino G., Mozes B. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am J Cardiol. 81:1998;7-11.
3. Gowda M.S., Vacek J.L., Hallas D. One-year outcomes of diabetic versus nondiabetic patients with non-Q-wave acute myocardial infarction treated with percutaneous transluminal coronary angioplasty. Am J Cardiol. 81:1998;1067-1071.
4. Barsness G.W., Peterson E.D., Ohman E.M., et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. 96:1997;2551-2556.
5. Aronson D., Rayfield E.J., Chesebro J.H. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 126:1997;296-306.
6. Ellis S.G., Narins C.R. Problem of angioplasty in diabetes. Circulation. 96:1997;1707-1710.
7. Mak K.H., Moliterno D.J., Granger C.B., et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 30:1997;171-179.
8. Stein B., Weintraub W.S., Gebhart S.P., et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 91:1995;979-989.
9. Carrozza J.P., Ho K.K., Neimann D., Kuntz R.E., Cutlip D.E. Diabetes mellitus is associated with adverse 6-month angiographic and clinical outcome following coronary stenting. (abstr) Circulation. 98:1998;I79.
10. Rankin J.M., Buller C.E., Al-Rashdan I.R., et al. Coronary angioplasty in diabetics have outcomes improved in the stent era? (abstr) Circulation. 98:1998;I79.
11. Marso S.P., Ellis S.G., Bhatt D.L., Sapp S.K., Emanuelsson H., Topol E.J. The stenting in diabetics debate insight from the large GUSTO-IIb experience with extended follow-up . (abstr) Circulation. 98:1998;I78.
12. Gu K., Cowie C.C., Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA. 281:1999;1291-1297.
13. Amos A.F., McCarty D.J., Zimmet P. The rising global burden of diabetes and its complications estimates and projections to the year 2010 . Diabet Med. 14:1997;S1-S85.
14. Zimmet P.Z., Alberti K.G. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus an epidemic in progress . Lancet. 350:(Suppl):1997;SI1-SI4.
15. Iwase E., Tawata M., Aida K., et al. A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. Metabolism. 47:1998;699-705.
16. Knobler H., Savion N., Shenkman B., Kotev-Emeth S., Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res. 90:1998;181-190.
17. Tschoepe D., Roesen P. Heart disease in diabetes mellitus a challenge for early diagnosis and intervention . Exp Clin Endocrinol Diabetes. 106:1998;16-24.
18. Tschoepe D., Driesch E., Schwippert B., Lampeter E.F. Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. Diabetologia. 40:1997;573-577.
19. Park S.H., Marso S.P., Forudi F., Lincoff A.M. Diabetes and the response to arterial injury. (abstr) Circulation. 98:1998;I8.
20. Akasaka T., Yoshida K., Hozumi T., et al. Retinopathy identifies marked restriction of coronary flow reserve in patients with diabetes mellitus. J Am Coll Cardiol. 30:1997;935-941.
21. Yokayama I., Momomura S.I., Ohtake T., et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 30:1997;1472-1477.
22. Calles-Escandon J., Mirza S.A., Sobel B.E., Schneider D.J. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 47:1998;290-293.
23. Topol E.J., Califf R.M., Weisman H.F., et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis results at six months. The EPIC Investigators . Lancet. 343:1994;881-886.
24. 3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA. 278:1997;479-484.
25. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
26. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE Study . Lancet. 349:1997;1429-1435.
27. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II . Lancet. 349:1997;1422-1428.
28. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy . N Engl J Med. 339:1998;436-443.
29. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:1998;1488-1497.
30. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. 96:1997;1445-1453.
31. Lincoff A.M., Califf R.M., Moliterno D.J., et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med. 341:1999;319-327.
32. Marso S.P., Tanguay J.F., Bhatt D.L., Kleiman N.S., Hammoud T., EJ T. Optimizing the percutaneous coronary interventional strategy for diabetics - the EPISTENT experience. (abstr) Circulation. 98:1998;400A.
33. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
34. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
35. Modan M., Karasik A., Halkin H., et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension. Diabetologia. 29:1986;82-89.
36. Stone N.J. Diet, nutritional issues, and obesity. Topol E.J. Comprehensive Cardiovascular Medicine. 1998;45-72 Lippincott-Raven, Philadelphia.
37. Topol EJ. EPISTENT Trial: 1-Year results. Presented at the 1998 Annual Meeting of the American Heart Association, Dallas, Texas.
38. Abizaid A., Kornowski R., Mintz G.S., et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 32:1998;584-589.
39. Van Belle E., Bauters C., Hubert E., et al. Restenosis rates in diabetic patients a comparison of coronary stenting and balloon angioplasty in native coronary vessels . Circulation. 96:1997;1454-1460.
40. Lincoff A.M. Does stenting prevent diabetic arterial shrinkage after percutaneous coronary revascularization? Circulation. 96:1997;1374-1377.
41. O'Keefe J.H., Blackstone E.H., Sergeant P., McCallister B.D. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J. 19:1998;1696-1703.
42. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease the Bypass Angioplasty Revascularization Investigation (BARI) . Circulation. 96:1997;1761-1769.
43. King S.B. Trying to understand BARI. J Am Coll Cardiol. 30:1997;426-427.
44. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 335:1996;217-225.
45. Detre K.M., Guo P., Holubkov R., et al. Coronary revascularization in diabetic patients a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI) . Circulation. 99:1999;633-640.
46. O'Neill W.W. Multivessel balloon angioplasty should be abandoned in diabetic patients. J Am Coll Cardiol. 31:1998;20-22.
47. Goldberg S., Savage M.P., Fischman D.L. The interventional cardiologist and the diabetic patient. Have we pushed the envelope too far or not far enough? Circulation. 94:1996;1804-1806.
48. Serruys P.W., Unger F., van Herwerden L., et al. Arterial revascularization therapy study the ARTS study, a randomized trial of bypass-surgery versus stenting in multivessel coronary artery disease . (abstr) Circulation. 98:1998;I498.
49. Kuntz R.E. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy the diabetes-percutaneous transluminal coronary angioplasty dilemma . Circulation. 99:1999;847-851.
50. Rozenman Y., Sapoznikov D., Mosseri M., et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation . J Am Coll Cardiol. 30:1997;1420-1425.
51. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
52. Baumgartner-Parzer S.M., Tschoepe D. Role of adhesion molecules in diabetes mellitus. Horm Metab Res. 29:1997;613.
53. Tschoepe D., Rauch U., Schwippert B. Platelet-leukocyte cross-talk in diabetes mellitus. Horm Metab Res. 29:1997;631-635.
54. Coleman K.R., Braden G.A., Willingham M.C., Sane D.C. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor, reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res. 84:1999;1268-1276.
55. O'Neill W. The EXCITE Trial. Presented at the 1999 American College of Cardiology Annual Meeting, New Orleans, Louisiana, 1999.
56. Garratt K.N., Brady P.A., Hassinger N.L., Grill D.E., Terzic A., Holmes D.R. Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 33:1999;119-124.
57. Brady P.A., Terzic A. The sulfonylurea controversy more questions from the heart . J Am Coll Cardiol. 31:1998;950-956.
58. Cleveland J.C. Jr, Meldrum D.R., Cain B.S., Banerjee A., Harken A.H. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation. 96:1997;29-32.